Профилактика тромбогенных осложнений в онкоурологии
Автор: Жернов А.А., Качмазов А.А., Перепечин Д.В.
Журнал: Экспериментальная и клиническая урология @ecuro
Рубрика: Методические рекомендации
Статья в выпуске: 3, 2010 года.
Бесплатный доступ
Онкоурология, тромбогенные осложнения, профилактика, антикоагулянтная терапия, низкомолекулярный гепарин, фрагмин
Короткий адрес: https://sciup.org/142188237
IDR: 142188237
Список литературы Профилактика тромбогенных осложнений в онкоурологии
- Lyman G.H., Khorana A.A. Cancer, clots and consensus: new understanding of an old problem. J Clin Oncol. 2009. Oct. 10. 27 (29): 4821-6. Epub 2009. Sep 14.
- Минимальные клинические рекомендации Европейского общества медицинской онкологии (ESMO). Перевод -коллектив авторов. М. 2008.
- Zangari M., Fink L.M., Elice F., Zhan F., Adcock D.M., Tricot G.J. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol. 2009. Oct 10; 27 (29): 4865-73. Epub 2009 Aug 24.
- Cosgrove R.H., Zacharski L.R., Racine E., Andersen J.C. Improved cancer mortality with low-molecular-weight heparin treatment: a review of the evidence. Semin Thromb Hemost. 2002. Feb; 28(1):79-87.
- Kuderer N.M., Ortel T.L., Francis C.W. Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol. 2009. Oct 10; 27 (29): 4902-11. Epub 2009 Sep 8.
- Francis C.W. Prevention of venous thromboembolism in hospitalized patients with cancer. J Clin Oncol. 2009. Oct 10; 27 (29): 4874-80. Epub 2009 Aug 24.
- Connolly G.C., Khorana A.A. Emerging risk stratification approaches to cancerassociated thrombosis: risk factors, biomarkers and a risk score. Thromb Res. 2010. Apr; 125 Suppl 2: S1-7.
- Bergqvist et al.Tromboprophylactic effect of low molecular weight heparin starting in the evening before electivegeneral abdominal surgery. A comparison with low-dose heparin. Seminars in thrombosis and hemostasis -volume 16, supplement. 1990.
- Leizorovicz A., Cohen A.T., Turpie A.G., Olsson C.G., Vaitkus P.T., Goldhaber S.Z. PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004. Aug 17; 110 (7): 874-9. Epub 2004 Aug 2.
- Инструкции по медицинскому применению препарата ФрагминR к РУ П №147/01 от 14.01.2009, П №14647/02 от 16.01.2009, П №12506/01 от 13.01.2006.
- Lee A. et al. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Reccurent Venous Tromboembolism in Patients with Cancer. New Engl. J. Med. 349, 2, 2003.
- Schmid P., Fischer A.G., Wuillemin W.A. Low-molecular-weight heparin in patients with renal insufficiency. Swiss Med Wkly. 2009 Aug 8; 139 (31-32): 438-52. Review.
- James Douketis et al. FRCPC; for the Canadian Critical Care Trials Group. Prophylaxis Against Deep Vein Thrombosis in Critically Ill Patients With Severe Renal Insufficiency With the Low-Molecular-Weight Heparin Dalteparin. An Assessment of Safety and Pharmacodynamics: The DIRECT Study. Arch Intern Med. 2008; 168 (16): 1805-1812.
- Rabbat C.G., Cook D.J., Crowther M.A., McDonald E., Clarke F., Meade M.O., Lee K.A., Cook R.J. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency. J Crit Care. 2005. Dec; 20 (4): 357-63.
- American Society of Clinical Oncology Guideline: recommendations for venous tromboembolism prophylaxis and treatment in patients with cancer. Journal of Clinical oncology/Volume 25. Number 34. December. 2007.
Статья
